Det er ikke undersøgt, om sekundært manglende respons grundet udviklingen af antistoffer er mindre hyppig under Xeomin- behandling end under behandling med konventionelle præparater, der indeholder botulinum type A- toksinkomplekset.
It has not been investigated whether secondary non-response due to the development of antibodies is less frequent under Xeomin therapy than under treatment with conventional preparations containing the Botulinum toxin type A complex.